Revvity, Inc. (RVTY)

Market Cap	10.78B -30.2%
Revenue (ttm)	2.86B +3.7%
Net Income	241.20M -10.8%
EPS	2.07 -5.8%
Shares Out	113.38M
PE Ratio	45.95
Forward PE	17.58
Dividend	$0.28 (0.29%)
Ex-Dividend Date	Apr 17, 2026

Volume	1,616,916
Open	95.20
Previous Close	96.03
Day's Range	93.94 - 96.61
52-Week Range	81.36 - 120.39
Beta	1.09
Analysts	Buy
Price Target	113.00 (+18.89%)
Earnings Date	Feb 2, 2026

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and dise...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1937
• Employees: 11,000
• Stock Exchange: NYSE
• Ticker Symbol: RVTY
• Website: https://www.revvity.com

Financial Performance

In 2025, Revvity's revenue was $2.86 billion, an increase of 3.67% compared to the previous year's $2.76 billion. Earnings were $241.20 million, a decrease of -10.79%.

Analyst Summary

According to 15 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $113.0, which is an increase of 18.89% from the latest price.

Price Target

$113.0

(18.89% upside)

Analyst Consensus: Buy